Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
This study assessed the effects of tirofiban and statins on high-sensitivity C-reactive protein , interleukin-6 , and soluble CD40 lig and after percutaneous coronary intervention in patients who had stable coronary artery disease .  Tirofiban insignificantly limited the increase of soluble CD40 lig and after revascularization , especially in patients who had high levels of this marker at baseline ( p = 0.06 ) , whereas statins significantly inhibited increases in interleukin-6 and , to a lesser extent , high-sensitivity C-reactive protein without affecting the soluble CD40 lig and
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .